arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

VYNE Therapeutics Inc.

VYNE
$28.05 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
40 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
53
Health
Fair
Moderately Bearish
auto_awesome

Analytical Summary

VYNE Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $24.1M
Dividend Yield —
Revenue Growth 40.6% ↗
Op. Margin None
ROIC -14.1% ↗
FCF / Share $-2.32 ↘
Trailing P/E —
Price / Book 0.9x
FCF Yield —
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Jul 27, 2026.

40-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$97.00K
↑ +40.6% —
Net Income Profit after all expenses
$-3.01M
↑ +47.7% —
Operating Margin Operating profit as % of sales
-435.0%
↑ +1.4% —
FCF / Share Free cash flow per share
$-2.32
↓ -2333.1% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
9
Financial Health
97
Cash Quality ↑
75

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 12 years · 40 quarters